BioNTech Offloads Roche Costs and Buys FDA Speed, Even as a Dutch Court Finds a GSK Patent Infringed
Published on 11/13/2026 at 15:50 | Editorial boerse-global.de
BioNTech is simultaneously loosening one financial obligation and taking on another, a pair of moves that sketch out how the German biotech intends to allocate capital across its pipeline. On 3 November the company disclosed a shift in cost-sharing within its collaboration with Roche/Genentech, and on the same day it confirmed the purchase of a US regulatory voucher from Scholar Rock for $205 million in cash.
The Roche arrangement hinges on an option BioNTech has now exercised. From 1 January 2027, future research and development costs for the programme in question will fall in principle to Roche/Genentech. BioNTech keeps its entitlement to licensing fees should development and commercialisation succeed, meaning it retains an economic stake in any eventual payoff while handing the partner the future cost burden. The pancreatic cancer trial covered by the collaboration is to continue as planned.
A €2 Million Ruling, With Enforcement Deferred
Legal risk moved to the foreground the same week. According to media reports, the Hague division of the Unified Patent Court ruled on Tuesday that Comirnaty, the COVID-19 vaccine BioNTech developed with Pfizer, infringed a GSK patent covering RNA delivery. The court ordered the two companies to pay provisional damages of €2 million. Enforcement of the injunction has been suspended pending a final decision, with a three-month window allowed for the parties to reach a licensing agreement.
BioNTech shares slipped 2.7% yesterday. The report on the patent ruling does not establish a causal link between that decline and the court's decision.
Should investors sell immediately? Or is it worth buying BioNTech?
The Voucher and the Numbers Behind It
The FDA Priority Review Voucher is intended to support a future marketing application for a late-stage oncology candidate — a voucher for a submission still to come, not an approval already granted for a cancer drug. Completion of the Scholar Rock deal remains subject to customary conditions, including antitrust clearance.
Weighing on the other side of the ledger are the third-quarter figures published last week. Revenue came in at €1.29 billion, with a net profit of €184.5 million under IFRS. Alongside those results BioNTech raised its full-year 2026 revenue guidance and now expects between €1.7 billion and €1.9 billion. The quarterly figures describe results already booked; the range is the upgraded forecast.
The longer view is less comfortable. Across the first nine months of 2026 BioNTech reported a net loss of €1,168.2 million, which keeps the split between self-funded programmes and partnered ones a central question for investors.
Cost Cuts Meet Workforce Tension
Handelsblatt linked Tuesday's voucher purchase to cost reductions and the closure of German sites. The newspaper had reported on 3 November that the works council criticised management's handling of employees against a backdrop of planned site closures and job cuts.
That is the awkward side of the overhaul. Targeted investment and savings can coexist on paper, but the works council's objections expose the friction in execution. A convincing allocation of capital has to be judged both on development outcomes and on how the planned changes are carried through.
What matters most is the economic quality of the division of labour: BioNTech can shed research risk while keeping a share of later success, but the approach only holds up if the programmes advance and the contingent revenue claims actually turn into income.
Ad
BioNTech Stock: New Analysis - 13 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
